Results 131 to 140 of about 40,994 (257)

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

open access: yesArthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora   +5 more
wiley   +1 more source

Clinical Images: Sevoflurane‐induced periostitis

open access: yes
Arthritis &Rheumatology, EarlyView.
Christian Beyer   +3 more
wiley   +1 more source

A multifaceted interplay between hemophagocytosis, IL‐18 and type I IFN distinguishes Still disease from other autoinflammatory diseases

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The unknown pathophysiology and the lack of specific features for systemic Juvenile Idiopathic arthritis and adult‐onset Still disease (collectively Still disease/SD) delays diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory diseases ...
Yvonne M. Mueller   +17 more
wiley   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

open access: yes
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic   +2 more
wiley   +1 more source

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith   +23 more
wiley   +1 more source

Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg‐IL‐2 axis emerge in ...
Justus Ohmes   +10 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy